(HealthDay News) — Patients with treatment-resistant hypertension who receive baxdrostat versus placebo have dose-dependent reductions in systolic blood pressure at 12 weeks, according to a study published online in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2022, held from Nov. 5 to 7 in Chicago.
Mason W. Freeman, MD, from CinCor Pharma in Boston, and colleagues conducted a multicenter, placebo-controlled trial involving patients with treatment-resistant hypertension with blood pressure of 130/80 mm Hg or higher who were receiving stable doses of at least 3 antihypertensive agents, including a diuretic. Patients were randomly assigned to receive baxdrostat (0.5, 1, or 2 mg) once daily for 12 weeks or placebo; 248 patients completed the trial.
The researchers found that there were dose-dependent changes in systolic blood pressure of −20.3, −17.5, −12.1, and −9.4 mm Hg, respectively, in the 2-, 1-, and 0.5-mg, and placebo groups. The differences in changes in systolic blood pressure between the 2-mg and placebo groups and between the 1-mg and placebo groups (−11.0 and −8.1 mm Hg, respectively) were statistically significant. There were no deaths during the trial, no serious adverse events were attributed to baxdrostat, and no cases of adrenocortical insufficiency occurred. In 2 patients, there were baxdrostat-related increases seen in the potassium level of 6.0 mmol/L or greater; these did not recur after drug withdrawal and reinitiation.
“Aldosterone synthase inhibition with baxdrostat led to substantial reductions in systolic and diastolic blood pressure in patients with treatment-resistant hypertension,” the authors write.
Several authors disclosed financial ties to CinCor Pharma, which manufactures baxdrostat and funded the trial.